None listed
Conditions
Brief summary
The aim of the study is to examine the safety and efficacy of cannabidiol (CBD) in the inpatient management of cannabis withdrawal in an open label study. Specifically the study will assess the impact of CBD on the number and severity of withdrawal symptoms, detoxification completion and adverse events in n=5, using an intention to treat analysis.
Interventions
Single subject repeated measures design of an open label administration of Cannabidiol to 5 subjects withdrawing from cannabis use in an inpatient setting. 300mg of CBD will be administered once on day 1, twice bd on days 2-5 and once on day 6. participants will be discharged on day 7. CBD will be administered orally in capsules.
Sponsors
UNSW
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Cannabis dependency Adult
Exclusion criteria
Poly substance dependence, Co-morbid Mental Health Diagnosis, Intellectual disability, Substance abuse treatment in previous 30 days, Evidence of severe medical condition (cardiac, renal, hepatic), Pregnant women or those wishing to start a family imminently, not willing to abide by NSW Health rules for inpatient admission.
Outcome results
None listed